Salla Disease Mutation Analysis
Salla disease is a very rare autosomal recessive lysosomal storage disease resulting from mutations in the SLC17A5 gene, located on chromosome 6q13. The SLC17A5 gene codes for a lysosomal membrane protein (sialin) necessary for the transport of sialic acid out of lysosomes. Mutations result in an overabundance of sialic acid in cells which can manifest as: nystagmus, hypotonia, and cognitive impairment due to abnormal CNS axon myelination. Salla disease is incurable; treatment includes supportive care for symptoms. Salla disease can be further classified into three subtypes, depending on the severity of disease.
Salla disease (SD):
- Least severe phenotype of disease subtypes
- Normal appearance and neurological findings at birth
- Slow, progressive neurological deterioration
- Clinical features: spasticity, seizures, ataxia, moderate to severe psychomotor retardation
- Life expectancy may be decreased in certain individuals
Intermediate Severe Salla Disease (SASD):
- Disease symptoms intermediate between SD and ISSD
Infantile Free Sialic Acid Storage Disease (ISSD):
- Most severe phenotype of disease subtypes
- Often presents prenatally or during the neonatal period as hydrops fetalis with or without isolated ascites
- Clinical features: severe developmental delay, hepatosplenomegaly, cardiomegaly, dysostosis multiplex
- Death usually occurs during early childhood
- Carrier testing for at risk individuals with prior identification of disease causing mutations in a family member
- Prenatal or preimplantation genetic diagnosis (PGD) for at risk pregnancies
- To confirm/establish a diagnosis of Salla disease in individuals presenting with clinical features suggestive of a sialic acid storage disorder
Negative:
Mutation not detected.
The presence of a free sialic acid storage disorder cannot be completely excluded. Rare polymorphisms exist and can lead to false negative or false positive results. Results should be interpreted within the context of previous laboratory testing, clinical presentation, and family history. Additional testing is recommended for discordant results/findings.
Positive:
A mutation was detected in the SLS17A5 gene.
Interpretive report includes mutation location, change in DNA sequence, and resulting amino acid change.
Negative for mutation analyzed (Mutation not detected)
Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices. Buccal swab is also used.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
Prenatal testing: Amniotic fluid, Chorionic villi, cultured amniocytes, cultured chorionic villi. Maternal blood sample must accompany all prenatal testing requests.
- Pediatr Neurol. 2002 Apr;26(4):267-73. [PMID: 11992753]
- Genet Test. 2003 Summer;7(2):113-21. [PMID: 12885332]
- Dev Med Child Neurol. 2004 Dec;46(12):832-7. [PMID: 15581157]
- Am J Med Genet. 1999 Feb 19;82(5):385-91. [PMID: 10069709]